Abstract
A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as Ridogrel (1).
MeSH terms
-
Animals
-
Drug Design
-
Enzyme Inhibitors / chemistry*
-
Humans
-
In Vitro Techniques
-
Indicators and Reagents
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / chemistry*
-
Platelet Membrane Glycoproteins / antagonists & inhibitors*
-
Platelet Membrane Glycoproteins / chemistry
-
Rabbits
-
Receptors, Cell Surface*
-
Receptors, G-Protein-Coupled*
-
Structure-Activity Relationship
-
Thromboxane-A Synthase / antagonists & inhibitors*
-
Thromboxane-A Synthase / chemistry
Substances
-
Enzyme Inhibitors
-
Indicators and Reagents
-
Platelet Aggregation Inhibitors
-
Platelet Membrane Glycoproteins
-
Receptors, Cell Surface
-
Receptors, G-Protein-Coupled
-
platelet activating factor receptor
-
Thromboxane-A Synthase